TI
ALXO icon

Trexquant Investment’s ALX Oncology ALXO Stock Holding History

Trexquant Investment’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,990
Closed -$234K – 1494
2024
Q1 		$234K Buy
+20,990
New +$295K ﹤0.01% 1340
2023
Q4 		– Sell
-14,269
Closed -$68.5K – 1392
2023
Q3 		$68.5K Sell
14,269
-36,162
-72% -$196K ﹤0.01% 1407
2023
Q2 		$379K Buy
50,431
+7,162
+17% +$46.9K 0.01% 1109
2023
Q1 		$196K Buy
43,269
+26,520
+158% +$201K 0.01% 1324
2022
Q4 		$189K Buy
+16,749
New +$188K 0.01% 1256
2022
Q3 		– Sell
-22,211
Closed -$180K – 1329
2022
Q2 		$180K Buy
+22,211
New +$242K 0.01% 1377
2022
Q1 		– Sell
-28,678
Closed -$616K – 1314
2021
Q4 		$616K Buy
28,678
+25,280
+744% +$1.09M 0.04% 556
2021
Q3 		$251K Sell
3,398
-843
-20% -$56.2K 0.02% 842
2021
Q2 		$232K Buy
+4,241
New +$254K 0.02% 833

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Trexquant Investment's ALXO Position: Q2 2024 in Review

Trexquant Investment sold out of ALX Oncology (ALXO) in Q2 2024, closing a stake of 20,990 shares — an estimated $234K sold.

Trexquant Investment first reported a position in ALXO in Q2 2021 and held it in 9 quarters. The position peaked at $616K in Q4 2021. 111 funds tracked by Wall St. Rank hold ALXO as of Q2 2024.

  • Trexquant Investment reported no remaining ALX Oncology position as of Q2 2024 after selling out during the quarter.
  • Trexquant Investment sold 20,990 ALX Oncology shares in Q2 2024, an estimated $234K.
  • Trexquant Investment first reported a position in ALX Oncology in Q2 2021 and held it in 9 quarters.
  • Trexquant Investment's ALX Oncology position peaked at $616K in Q4 2021.
  • 111 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2024.

Based on Trexquant Investment's 13F filing for Q2 2024, filed 13 Aug 2024.